Eli Lilly and Company LLY
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Eli Lilly and Company is a mega-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $1.02T, based in the USA.
It employs about 50,000 people and has been listed since Jan 13, 1978.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.
Cheap or expensive? priced in line with its group
Its price-to-earnings (P/E) is 38.3 versus 33.4 for 4 direct peers — priced in line with its group.
Revenue is growing 48% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 24.4 — they expect higher earnings.
The average analyst price target is 1328.83, 16% above the current price (their view, not ours).
The stock sits at 71% of its one-year range (0% = the low, 100% = the high).
The risks
- • Net debt is 1.4× shareholders' equity — high leverage.
Strengths
- ✅ Profitable — 31 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Most analysts rate it buy (25 vs 2).
- ✅ Revenue is growing 48% a year.
- ✅ Pays a dividend (0.6% a year).
What changed this week
Over the past week the stock fell 3.4% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- Woman, 38, Inherits $1.4M And Finds Her Mom's Advisor Charges 1.25% — Her Brother Says Firing Him Would Be 'Disrespectful' finance.yahoo.com · 2026-10-02
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL finance.yahoo.com · 2026-10-02
- Correction: Top Midday Decliners finance.yahoo.com · 2026-10-02
- LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies finance.yahoo.com · 2026-10-02
- Twist Bioscience (TWST) Stock Could Be Reasonable On Its 9x Three Year Run finance.yahoo.com · 2026-10-02
- Sector Update: Healthcare Stocks Fall Late Afternoon finance.yahoo.com · 2026-10-01
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.